09.02.2014 Views

home edit2 whole TSD November 2002 PDF format - OEHHA

home edit2 whole TSD November 2002 PDF format - OEHHA

home edit2 whole TSD November 2002 PDF format - OEHHA

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

incidence of mammary tumors. Control groups included a negative control (sesame oil only) and a<br />

positive control (7,12-dimethylbenz[a]anthracene). No tumors were observed in treated animals, but a<br />

3% incidence was observed in the negative controls and 100% incidence in positive control animals.<br />

Osanai et al. (1976) treated 26 male ICR/JCL mice (plus 39 untreated control mice) with feed<br />

containing 0.1% 3,3’-dichlorobenzidine for 12 months with an interim sacrifice group at 6 months.<br />

Hepatomas were observed in all treated animals at 6 and 12 months (p < 0.01) and among control<br />

animals at an incidence of 0%, 9.5% (2/21) and 38.55% (5/13) at 6,12, and 18 months, respectively.<br />

Tatematse et al. (1977) fed 22 male Wistar rats a diet containing 0.3% 3,3’-dichlorobenzidine alone or<br />

in sequence with o-N-butyl-N-(4-hydroxybutyl)nitrosamine (0.1% in drinking water), N-[4-(5-nitro-2-<br />

furyl)-2-thiazolyl]formamide (0.15% in the diet) and N-fluorenylacetamide (0.025% in the drinking<br />

water) over a four week period. Twelve untreated animals served as controls. Animals were observed<br />

for a 40 week period. Only animals receiving combined exposures showed effects which included<br />

some bladder tumors and histological changes of the liver.<br />

Saffiotti et al. (1967) and Sellakumar et al. (1969) report on a feeding study in which Syrian golden<br />

hamsters (30/sex/group) were exposed to 0.1% or 0.3% 3,3’-dichlorobenzidine in feed; an untreated<br />

control group (30/sex) was included. No significant carcinogenic effects were observed in the 0.1%<br />

3,3’-dichlorobenzidine group. The 0.3% 3,3’-dichlorobenzidine group, however, showed increased<br />

incidence of transitional cell carcinomas of the bladder (4/30 treated, 0/30 control; p = 0.056 by<br />

Fisher’s exact test). Other observations included some liver-cell and cholangiomatous tumors.<br />

A single study suggests that 3,3’-dichlorobenzidine may act as a transplacental carcinogen (Golub et al.,<br />

1974). Pregnant female BALB/c mice given 2 mg 3,3’-dichlorobenzidine (in 0.1 ml sesame oil) five<br />

times during the last week of pregnancy, showed increased incidence of lymphoid leukemia among the<br />

offspring of exposed animals (7/24 treated, 0/30 control; p < 0.01). This effect, however, could also<br />

have occurred by exposure via lactation.<br />

IV.<br />

DERIVATION OF CANCER POTENCY<br />

Basis for Cancer Potency<br />

An IARC (1982) review of the human epidemiological studies deemed them inadequate for evaluating<br />

carcinogenicity due to the relatively small size of the cohorts, inadequate time since first exposure,<br />

and/or incomplete follow-up of exposed workers.<br />

The only carcinogenesis studies amenable to the development of cancer potency values are those<br />

conducted by Stula et al. (1975, 1978) showing the induction of granulocytic leukemia, mammary<br />

adenocarcinoma, and Zymbal gland carcinoma in rats and papillary transitional cell carcinomas of the<br />

bladder and hepatocellular carcinomas in beagle dogs exposed to 3,3’-dichlorobenzidine. Limitations<br />

of the other available studies including poor study design, inadequate scope of endpoints, and unclear<br />

249

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!